Melanotan-2 research has explored melanocortin agonist activity in neuroendocrine research models (Learn more), melanogenesis, receptor subtype selectivity and behavioural signalling pathways. Some of this literature originates from melanocortin-receptor pharmacology research alongside other related compounds such as Melanotan-1. The results vary considerably between models and are best read as laboratory observations, not as established cosmetic or therapeutic effects.
Seven residues in a ring: how Melanotan-2 was designed
By the late 1980s the Arizona melanotropin group already had a superpotent linear analogue, [Nle4, D-Phe7]-alpha-MSH, now sold as Melanotan-1. Fahad Al-Obeidi, Ana Maria Castrucci, Mac Hadley and Victor Hruby then asked whether a much shorter, conformationally locked peptide could do the same job. Using molecular dynamics simulations of alpha-MSH and its potent relatives as a guide, they designed fragments in which two side chains are stitched together by an amide bond, forming a lactam ring.
Their 1989 Journal of Medicinal Chemistry paper described seven cyclic peptides tested on frog and lizard skin. The best pairing joined aspartic acid at position 5 to lysine at position 10, and trimming the chain to residues 4 to 10 gave Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, the compound that became Melanotan-2. It keeps the norleucine and D-phenylalanine of its linear predecessor, but the ring holds the receptor-binding His-D-Phe-Arg-Trp segment in a compact, pre-organised shape. Several of these lactams were far more potent and longer acting than alpha-MSH, making the design an influential template.
A broad agonist across four melanocortin receptors
In the early 1990s the melanocortin family grew from two known receptors to five. MC1R had been cloned from melanocytes and MC2R from the adrenal gland, and three more followed: MC3R and MC4R, found mainly in the brain, and MC5R, spread across peripheral tissues. A 1995 study by Hruby, Cone and colleagues confirmed that MC2R recognises essentially only ACTH, while MC1R, MC3R, MC4R and MC5R all respond to alpha-MSH, to Melanotan-1 and to the cyclic Melanotan-2.
That non-selectivity is a feature, not a flaw, in pharmacology. Because Melanotan-2 activates the four alpha-MSH-responsive receptors strongly and reliably, it serves as a reference full agonist: new compounds are benchmarked against it, and receptor-expressing cell lines are validated with it. The same 1995 paper showed that putting a bulkier aromatic residue at position 7 of the Melanotan-2 ring could turn agonists into potent, selective antagonists, opening the door to tools that switch individual receptors off.
Agouti mice and the brain’s melanocortin circuits
One of the best-known uses of Melanotan-2 came from mouse genetics. Mice carrying dominant agouti alleles have yellow coats, because agouti protein blocks MC1R in hair follicles. Those mice also become obese, and Roger Cone’s laboratory suspected the reason was that agouti protein, expressed outside the skin, was also blocking MC4R in the hypothalamus.
To test the idea, Fan and colleagues reported in Nature in 1997 that Melanotan-2 delivered directly into the brain ventricles of mice reduced feeding in four different mouse models, and that SHU9119, a cyclic antagonist built on the Melanotan-2 scaffold, completely blocked the effect. Given alone, SHU9119 increased feeding. The study established that central melanocortin neurons exert a constant restraining signal in mice and linked a coat-colour gene to brain receptor signalling.
Bremelanotide: Melanotan-2’s close chemical relative
Bremelanotide, also known as PT-141, has the same acetylated norleucine and the same seven-residue lactam ring as Melanotan-2. The difference lies at the very end of the chain. Melanotan-2 finishes with a C-terminal amide (-CONH2), while bremelanotide finishes with a free carboxylic acid (-COOH). That single swap of an NH2 group for an OH changes the formula from C50H69N15O9 to C50H68N14O10 and the average molecular weight from 1024.2 to 1025.2 g/mol. Because converting the amide to the acid is a simple deamidation, bremelanotide is often described as a likely metabolite of Melanotan-2.
Developed by Palatin Technologies, bremelanotide was approved by the US FDA on 21 June 2019 under the brand name Vyleesi, as a treatment for acquired, generalised hypoactive sexual desire disorder in premenopausal women. Melanotan-2 itself holds no such approval. Researchers who want the acid form can find it on our PT-141 page.
